OBJECTIVE: Selection of specific human leukocyte antigen (HLA)-restricted cytotoxic T-lymphocyte (CTL) escape mutations in key Gag epitopes has been associated with loss of HIV immune control on an individual basis. Here we undertake a population-based identification of HLA-associated polymorphisms in Gag and investigate their relationship with plasma viral load. DESIGN: Cross-sectional analysis of 567 chronically HIV subtype B-infected, treatment-naive individuals. METHODS: HLA class I-associated Gag substitutions were identified using phylogenetically corrected analysis methods featuring a multivariate adjustment for HLA linkage disequilibrium and a q-value correction for multiple tests. Presence of HLA-associated substitutions and markers of HIV disease status were correlated using Spearman's rank test. RESULTS: We have created a gene-wide map of HLA class I-associated substitutions in HIV-1 subtype B Gag. This features 111 HLA-associated substitutions occurring at 51 of 500 Gag codons, more than 50% of which occur within published and/or putative HLA-restricted CTL epitopes. A modest inverse correlation was observed between the total number of HLA-associated Gag polymorphic sites within each individual and plasma viral load in chronic untreated infection (R = -0.17, P < 0.0001), supporting the hypothesis that a broad ability to target Gag in vivo contributes to viral control. A modest positive correlation was observed between the proportion of these sites exhibiting HLA-associated substitutions and plasma viral load (R = 0.09, P = 0.03), consistent with a loss of viremia control with the accumulation of CTL escape mutations. CONCLUSION: Results contribute to our understanding of immune-driven viral adaptation and suggest that the accumulation of CTL escape mutations in Gag results in clinically detectable consequences at the population level. These data have implications for HIV vaccines.
OBJECTIVE: Selection of specific human leukocyte antigen (HLA)-restricted cytotoxic T-lymphocyte (CTL) escape mutations in key Gag epitopes has been associated with loss of HIV immune control on an individual basis. Here we undertake a population-based identification of HLA-associated polymorphisms in Gag and investigate their relationship with plasma viral load. DESIGN: Cross-sectional analysis of 567 chronically HIV subtype B-infected, treatment-naive individuals. METHODS: HLA class I-associated Gag substitutions were identified using phylogenetically corrected analysis methods featuring a multivariate adjustment for HLA linkage disequilibrium and a q-value correction for multiple tests. Presence of HLA-associated substitutions and markers of HIV disease status were correlated using Spearman's rank test. RESULTS: We have created a gene-wide map of HLA class I-associated substitutions in HIV-1 subtype BGag. This features 111 HLA-associated substitutions occurring at 51 of 500 Gag codons, more than 50% of which occur within published and/or putative HLA-restricted CTL epitopes. A modest inverse correlation was observed between the total number of HLA-associated Gag polymorphic sites within each individual and plasma viral load in chronic untreated infection (R = -0.17, P < 0.0001), supporting the hypothesis that a broad ability to target Gag in vivo contributes to viral control. A modest positive correlation was observed between the proportion of these sites exhibiting HLA-associated substitutions and plasma viral load (R = 0.09, P = 0.03), consistent with a loss of viremia control with the accumulation of CTL escape mutations. CONCLUSION: Results contribute to our understanding of immune-driven viral adaptation and suggest that the accumulation of CTL escape mutations in Gag results in clinically detectable consequences at the population level. These data have implications for HIV vaccines.
Authors: Christoph T Berger; Nicole Frahm; David A Price; Beatriz Mothe; Musie Ghebremichael; Kari L Hartman; Leah M Henry; Jason M Brenchley; Laura E Ruff; Vanessa Venturi; Florencia Pereyra; John Sidney; Alessandro Sette; Daniel C Douek; Bruce D Walker; Daniel E Kaufmann; Christian Brander Journal: J Virol Date: 2011-07-13 Impact factor: 5.103
Authors: Arne Schneidewind; Zabrina L Brumme; Chanson J Brumme; Karen A Power; Laura L Reyor; Kristin O'Sullivan; Adrianne Gladden; Ursula Hempel; Thomas Kuntzen; Yaoyu E Wang; Cesar Oniangue-Ndza; Heiko Jessen; Martin Markowitz; Eric S Rosenberg; Rafick-Pierre Sékaly; Anthony D Kelleher; Bruce D Walker; Todd M Allen Journal: J Virol Date: 2008-12-17 Impact factor: 5.103
Authors: Toshiyuki Miura; Chanson J Brumme; Mark A Brockman; Zabrina L Brumme; Florencia Pereyra; Brian L Block; Alicja Trocha; Mina John; Simon Mallal; P Richard Harrigan; Bruce D Walker Journal: J Virol Date: 2009-01-19 Impact factor: 5.103
Authors: Vladimir Novitsky; Rui Wang; Jeannie Baca; Lauren Margolin; Mary F McLane; Sikhulile Moyo; Erik van Widenfelt; Joseph Makhema; M Essex Journal: Virology Date: 2011-10-19 Impact factor: 3.616
Authors: Estibaliz Lazaro; Carl Kadie; Pamela Stamegna; Shao Chong Zhang; Pauline Gourdain; Nicole Y Lai; Mei Zhang; Sergio A Martinez; David Heckerman; Sylvie Le Gall Journal: J Clin Invest Date: 2011-05-09 Impact factor: 14.808
Authors: Anne Piantadosi; Bhavna Chohan; Dana Panteleeff; Jared M Baeten; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh Journal: AIDS Date: 2009-03-13 Impact factor: 4.177
Authors: Santiago Avila-Rios; Christopher E Ormsby; Jonathan M Carlson; Humberto Valenzuela-Ponce; Juan Blanco-Heredia; Daniela Garrido-Rodriguez; Claudia Garcia-Morales; David Heckerman; Zabrina L Brumme; Simon Mallal; Mina John; Enrique Espinosa; Gustavo Reyes-Teran Journal: Retrovirology Date: 2009-08-10 Impact factor: 4.602